• Disc Medicine CEO John Quisel
    Image attribution tooltip
    Permission granted by Disc Medicine

    Gemini’s fall gives Disc a way around biotech’s IPO slump

    The biotech’s failed attempt to develop an eye drug has ended in a reverse merger that gives startup Disc Medicine a fast path to the public markets.

    By Aug. 10, 2022
  • The Merck & Co. sign at the company's building in Summit, New Jersey.
    Image attribution tooltip
    Kena Betancur via Getty Images
    Emerging biotech

    A biotech startup gives Merck its next shot at treating Alzheimer’s

    Boston-based Cerevance is searching for new drug targets for neurological diseases like Alzheimer’s, although CEO Craig Thompson wouldn’t reveal what its work with Merck will take aim at.

    By Aug. 9, 2022
  • A sign for Pfizer is seen outside the Pfizer headquarters on November 9, 2020 in New York City.
    Image attribution tooltip
    David Dee Delgado via Getty Images

    Pfizer buys sickle cell drugmaker Global Blood for $5.4B

    The acquisition gives Pfizer access to Oxbryta, an approved drug for the blood condition, as well as two experimental medicines.

    By , Updated Aug. 8, 2022
  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences

    How a small UK biotech ended up in Gilead’s hands

    MiroBio, which was spun out of the University of Oxford three years ago, drew Gilead’s interest with its autoimmune disease research.

    By Aug. 5, 2022
  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.

    Amgen bets almost $4B on a biotech and its inflammation drugs

    The deals hands Amgen a few clinical programs and a marketed therapy in Tavneos, which was approved last year to treat a group of autoimmune diseases.

    By Aug. 4, 2022
  • A white lab coat showing an AbCellera logo
    Image attribution tooltip
    Courtesy of AbCellera
    Emerging biotech

    AbCellera inks another venture partnership, this time with Atlas

    One week after striking a deal with Versant, the antibody specialist is teaming up with Atlas to provide drug candidates to an undisclosed startup backed by the biotech investor.

    By Aug. 3, 2022
  • The outside of an AbbVie building, with the company's logo displayed.
    Image attribution tooltip

    AbbVie, targeting a well-known protein family, expands a partnership into neuroscience

    It’s the second deal in as many years between AbbVie and Sosei Heptares, which together have been trying to develop drugs that target so-called G protein-coupled receptors.

    By Aug. 2, 2022
  • An illustration of T cells attacking cancer cells
    Image attribution tooltip
    Meletios Verras via Getty Images

    Ipsen, continuing oncology push, pays a startup $45M for two cancer drugs

    The French company will work with Marengo Therapeutics in an alliance that could be worth as much as $1.6 billion.

    By Aug. 1, 2022
  • Image attribution tooltip
    Photo illustration by Maura Sadovi/BioPharma Dive; photograph by Carl Court via Getty Images

    US secures updated COVID boosters in $1.7B deal with Moderna

    Health officials are gearing up for a fall vaccination campaign and aim to deploy shots modified to better match circulating omicron subvariants.

    By July 29, 2022
  • Sekar Kathiresan and the Verve team ring the Nasdaq closing bell for their company's IPO in June.
    Image attribution tooltip
    Permission granted by Sekar Kathiresan

    Vertex, Verve team up to develop a gene editing drug for liver disease

    The deal, which is worth $60 million upfront, broadens Vertex’s reach into gene editing and expands Verve’s research beyond heart disease.

    By July 20, 2022
  • AbbVie, building eye-care business, pays $60M for implantable glaucoma treatment

    The pharma has secured an option to buy iSTAR Medical, which sells a small implant that helps lower eye pressure and is cleared for use in Europe.

    By Elise Reuter • July 20, 2022
  • Colonies of bacteria in MacConkey agar
    Image attribution tooltip
    Md Saiful Islam Khan via Getty Images

    Nestlé expands microbiome drug work with biotech deal

    The food giant will pay French company Enterome about $40 million to join in the development of an inflammatory bowel disease drug as well as other food allergy treatments.

    By July 18, 2022
  • Group of people working in a modern board room with augmented reality interface, all objects in the scene are 3D.
    Image attribution tooltip
    piranka via Getty Images

    Ultragenyx sells rare disease drug royalties to Canadian pension fund

    In exchange for $500 million, the fund, called OMERS, will get a 30% royalty on future sales of Ultragenyx’s drug Crysvita in the U.S. and Canada, where it’s approved to treat two rare conditions.

    By July 15, 2022
  • A 3D illustration of human lungs.
    Image attribution tooltip
    yodiyim via Getty Images

    Royalty Pharma buys rights to top-selling GSK drug in pair of deals

    The prolific biopharma dealmaker is paying Theravance $1.1 billion and Innoviva $282 million to acquire rights to royalties on GSK’s asthma and COPD drug Trelegy Ellipta.

    By Kristin Jensen • July 14, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images

    TherapeuticsMD buyout unravels as shareholders balk

    Too few investors in the women’s health company pledged their shares to the take-private offer from EW Healthcare Partners, killing the deal.

    By July 13, 2022
  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals

    Vertex acquires another maker of potentially curative diabetes treatments

    For $320 million, Vertex said it plans to buy ViaCyte in a deal that would provide “complementary assets, capabilities and technologies” to the ones it picked up through the 2019 acquisition of Semma Therapeutics.

    By July 11, 2022
  • Colonies of bacteria in MacConkey agar
    Image attribution tooltip
    Md Saiful Islam Khan via Getty Images

    Healthcare asset manager Innoviva buys another biotech at a bargain price

    Two months after acquiring Entasis Therapeutics, the firm reached a deal to buy La Jolla Pharmaceutical Co. at a fraction of what La Jolla was worth just a few years ago.

    By July 11, 2022
  • Image attribution tooltip
    Carl Court via Getty Images

    ADC Therapeutics cuts deal with Sobi to broaden reach of cancer drug

    The alliance comes on the heels of a change in leadership at ADC and will help ready the biotech to launch its lymphoma drug in Europe.

    By July 8, 2022
  • Beta-Amyloid Plaques and Tau in the Brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.

    AbbVie dials back partnership on experimental Alzheimer's drug

    While AbbVie is bailing on one of the two programs it paid Alector $205 million to acquire five years ago, work will continue on the second project. That drug, however, has shown safety signals.  

    By July 8, 2022
  • Image attribution tooltip
    400tmax via Getty Images

    Radius, fending off activists, outlines pitch for $890 million buyout

    The biotech detailed the process that led to its take-private offer last month, aiming to win the support of shareholders, including two firms that have pushed for change. 

    By July 8, 2022
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    After a lengthy drought, could biotech M&A be on the upswing?

    With at least 14 buyouts worth $50 million or more, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Some industry watchers expect that pace to continue. 

    By July 8, 2022
  • Federal Trade Commission
    Image attribution tooltip
    Carol Highsmith. (2005). "The Apex Building" [Photo]. Retrieved from Wikimedia Commons.

    As Merck closes in on Seagen, the FTC nears a key test on pharma deals

    An acquisition reportedly worth $40 billion or more and potentially signed within weeks could draw notable scrutiny from regulators and force the companies to divest certain drug programs.  

    By , July 7, 2022
  • A stock image of a calculator alongside financial numbers
    Image attribution tooltip
    atiatiati via Getty Images

    Two cancer biotechs merge, raise cash as sector-wide downturn continues

    Syros Pharmaceuticals and Tyme Technologies, shares of which trade near all-time lows, will combine and raise about $130 million in the latest example of how the industry’s slump is affecting publicly traded biotechs. 

    By July 5, 2022
  • Employees of CureVac work in a laboratory
    Image attribution tooltip
    Courtesy of CureVac

    CureVac sues rival COVID-19 vaccine maker BioNTech for patent infringement

    The biotech, whose own efforts to develop a COVID-19 vaccine have faltered, claims its inventions were crucial to the development of BioNTech’s top-selling coronavirus shot.

    By July 5, 2022
  • Image attribution tooltip
    Christopher Furlong via Getty Images

    With $100M AstraZeneca deal, a biotech and its investors engineer another buyout

    An entity originally known as Teneobio has now been the focus of three acquisition deals with large pharmaceutical companies since 2021, capitalizing on the industry’s growing interest in dual-acting antibody drugs.

    By July 5, 2022